ARRY Array BioPharma Inc.

-0.15  -1%
Previous Close 11.47
Open 11.44
Price To book 161.71
Market Cap 1944393644
Shares 171,766,223
Volume 2,932,162
Short Ratio 7.53
Av. Daily Volume 4,487,380

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial did not meet its primary endpoint - August 2016
Selumetinib - SELECT-1
Differentiated thyroid cancer
Phase 3 data released September 26, 2016 met primary endpoint. PDUFA date June 30, 2018 - no Adcom anticipated.
Binimetinib - COLUMBUS
BRAF mutant melanoma cancer
Phase 2 data presented at the European Society of Cardiology on August 30, 2016. Phase 3 trial to be initiated 2017.
ARRY 797
LMNA A/C-related dilated cardiomyopathy (DCM)
Phase 2 interim data due 2016 but no plans to advance program
ARRY-520 (Filanesib)
Refractory Multiple Myeloma Cancer
Phase 3 trial discontinued April 2016
Binimetinib - MILO
Recurrent low-grade serous ovarian cancer (LGSOC)
PDUFA date originally set for June 30, 2017. Announed withdrawl of NDA filing - March 20, 2017.
Binimetinib (NEMO)
NRAS melanoma - cancer
Data at ESMO September 2017. ORR 41%. Median duration of treatment was 5.6 months.
Encorafenib and cetuximab - BEACON CRC
BRAF-Mutant Colorectal Cancer

Latest News

  1. Cramer's lightning round: I like Altria Group, but it's n...
  2. Array BioPharma To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference
  3. Array BioPharma Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
  4. Mirati Skyrockets On Positive Data - Biotech Movers
  5. Today's Research Reports on Stocks to Watch: Halozyme Therapeutics and Array Biopharma
  6. Array BioPharma Announces Pricing of Public Offering of Common Stock
  7. Colorado biotech plans $200 million stock offering
  8. Array BioPharma Slides on Secondary Offering
  9. Array BioPharma shares slide on secondary offering announcement
  10. Array BioPharma Announces Proposed Public Offering of Common Stock
  11. Steven Cohen Dives Into Array BioPharma
  12. Array's NDAs for Melanoma Combo Accepted for Review by FDA
  13. Array BioPharma Announces FDA Acceptance For Review Of Binimetinib And Encorafenib New Drug Applications For Patients With Advanced BRAF-mutant Melanoma
  14. See what the IHS Markit Score report has to say about Array Biopharma Inc.
  15. ETFs with exposure to Array BioPharma, Inc. : September 12, 2017
  16. Array BioPharma And Others Shine At The ESMO 2017 Congress
  17. Today's Research Reports on Stocks to Watch: Array BioPharma and Kura Oncology
  18. Phase 3 COLUMBUS Part 2 Results in BRAF-Mutant Melanoma Presented at European Society for Medical Oncology Congress
  19. Array Resumes Trades After Unveiling Data In Colon Cancer Trial
  20. Array BioPharma, Inc. :ARRY-US: Earnings Analysis: Q4, 2017 By the Numbers : September 8, 2017

SEC Filings

  1. 8-K - Current report 171088311
  2. 424B5 - Prospectus [Rule 424(b)(5)] 171088216
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171083497
  4. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 171083305
  5. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 171083260
  6. DEF 14A - Other definitive proxy statements 171083237
  7. SC 13G - Statement of acquisition of beneficial ownership by individuals 171081694
  8. 8-K - Current report 171080391
  9. 8-K - Current report 171077848
  10. 8-K - Current report 171076427